BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26601565)

  • 1. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
    Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
    J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream.
    van Meurs T; van Doorn R; Kirtschig G
    Dermatol Surg; 2007 May; 33(5):623-6; discussion 626-7. PubMed ID: 17451589
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.
    Van Meurs T; Van Doorn R; Kirtschig G
    Dermatol Surg; 2010 Jun; 36(6):853-8. PubMed ID: 20618370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lentigo maligna with imiquimod before staged excision.
    Cotter MA; McKenna JK; Bowen GM
    Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod.
    Ramsdell AM; Zeitouni N
    Dermatol Surg; 2009 Feb; 35(2):287-90. PubMed ID: 19215272
    [No Abstract]   [Full Text] [Related]  

  • 7. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
    Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
    J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production.
    Martires KJ; Capaldi L; Pattee SF; Maloney ME; Bordeaux JS
    Arch Dermatol; 2010 Sep; 146(9):1047-8. PubMed ID: 20855714
    [No Abstract]   [Full Text] [Related]  

  • 9. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
    Kirtschig G; van Meurs T; van Doorn R
    Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance].
    Lorentzen HF; Weismann K
    Ugeskr Laeger; 2005 Sep; 167(39):3696-7. PubMed ID: 16219219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
    Fleming CJ; Bryden AM; Evans A; Dawe RS; Ibbotson SH
    Br J Dermatol; 2004 Aug; 151(2):485-8. PubMed ID: 15327559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lentigo maligna with imiquimod 5% cream.
    Hopson B; Richey D; Sajben FP
    J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical 5% imiquimod in the treatment of lentigo maligna.
    Wong JG; Toole JW; Demers AA; Musto G; Wiseman MC
    J Cutan Med Surg; 2012; 16(4):245-9. PubMed ID: 22784516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Videodermatoscopy of lentigo maligna treated with imiquimod.
    Micali G; Lacarrubba F; Nardone B; Nasca MR
    J Drugs Dermatol; 2008 Nov; 7(11):1077-80. PubMed ID: 19110742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases.
    de Troya-Martín M; Frieyro-Elicegui M; Fúnez Liébana R; Aguilar Bernier M; Fernández-Canedo NI; Blázquez Sánchez N
    Dermatol Surg; 2008 Nov; 34(11):1561-6. PubMed ID: 18798748
    [No Abstract]   [Full Text] [Related]  

  • 18. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients.
    Buettiker UV; Yawalkar NY; Braathen LR; Hunger RE
    Arch Dermatol; 2008 Jul; 144(7):943-5. PubMed ID: 18645150
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical imiquimod for periocular lentigo maligna.
    Demirci H; Shields CL; Bianciotto CG; Shields JA
    Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
    Powell AM; Robson AM; Russell-Jones R; Barlow RJ
    Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.